Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KYAT1 | Q16773 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807755 | 1.00 | GAA (0.42) | GAAMAPTP2RY14ATMKMT2A | |
| SCHEMBL4811515 | 0.91 | P2RY14 (0.49) | GAAMAPTP2RY14ATMKMT2A | |
| SCHEMBL4811518 | 0.91 | P2RY14 (0.49) | GAAMAPTP2RY14ATMKMT2A | |
| SCHEMBL11844704 | 0.78 | P2RY14 (0.43) | P2RY14ATMKMT2AEPHX1POLB | |
| SCHEMBL21104257 | 0.78 | ELANE (0.54) | GAAMAPTP2RY14ATMKMT2A | |
| SCHEMBL4808895 | 0.77 | MAPT (0.52) | GAAMAPTKMT2APOLBRAB9A | |
| SCHEMBL4808892 | 0.77 | MAPT (0.52) | GAAMAPTKMT2APOLBRAB9A | |
| SCHEMBL4814123 | 0.77 | DHODH (0.64) | GAAMAPTKMT2ADHODHPOLB | |
| SCHEMBL4814118 | 0.77 | DHODH (0.64) | GAAMAPTKMT2ADHODHPOLB | |
| SCHEMBL10077417 | 0.77 | MAPT (0.47) | GAAMAPTATMKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | disclosed |
| US-7375116-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-20 | — | — | US | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-7361670-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-22 | — | — | US | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GAA 4426/4885MAPT 3394/4885P2RY14 332/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GAA 4653/4885MAPT 3498/4885P2RY14 402/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GAA 4684/4885MAPT 3025/4885P2RY14 419/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GAA 4440/4885MAPT 3477/4885P2RY14 349/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | GAA 4534/4885MAPT 4133/4885P2RY14 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.